Kumor Marta, Bielicki Piotr, Przybyłowski Tadeusz, Rubinsztajn Renata, Zieliński Jan, Chazan Ryszarda
Katedra i Klinika Chorób Wewnętrznych, Pneumonologii i Alergologii Warszawskiego Uniwersytetu Medycznego.
Pneumonol Alergol Pol. 2011;79(3):173-83.
In OSAS patients CPAP therapy decreases cardiovascular morbidity and mortality. Homocysteine and leptin may play a role in development of ischaemic heart disease (IHD) in patients with OSAS. The aim of the study was to assess the influence of 3 month CPAP therapy on cardiovascular risk factors in patients with OSAS without IHD (pure OSAS) and with OSAS and IHD.
Therapy with CPAP was started in 42 OSAS without IHD (pure OSAS) and 23 OSAS and IHD patients. Plasma concentration of homocysteine, serum concentration of leptin, C-reactive protein (CRP), fibrinogen, lipids, and markers of visceral adiposity (MVA) were measured before and after treatment.
There were no significant changes in homocysteine, leptin, fibrinogen and CRP concentrations in neither group. In OSAS and IHD no change in serum lipids and MVA were found. In pure OSAS group total cholesterol and LDL cholesterol concentrations significantly decreased (202.5 ± 38.5 mg/dl v. 186.7 ± 33.5 mg/dl, p = 0.001 and 127.3 ± 32.9 mg/dl v. 116.4 ± 26.9 mg/dl, p = 0.02, respectively). Triglycerides did not significantly change (p = 0.09). There were no significant changes in BMI (30.4 ± 3.8 v. 30.6 ± 3.6, p = 0.5), waist circumference (108.5 ± 8.0 cm v. 107.0 ± 7.5 cm, p = 0.09) and waist to hip ratio (1.03 ± 0.04 v. 1.01 ± 0.03, p = 0.07).
Three month CPAP therapy did not change homocysteine and leptin concentration in neither group. However, it significantly decreased serum lipids concentration in patients with pure OSAS, but not in patients with OSAS and IHD, suggesting beneficial effects of CPAP therapy on cardiovascular risk factors.
在阻塞性睡眠呼吸暂停低通气综合征(OSAS)患者中,持续气道正压通气(CPAP)治疗可降低心血管疾病的发病率和死亡率。同型半胱氨酸和瘦素可能在OSAS患者缺血性心脏病(IHD)的发生发展中起作用。本研究的目的是评估3个月CPAP治疗对无IHD的OSAS患者(单纯OSAS)以及合并OSAS和IHD患者心血管危险因素的影响。
42例无IHD的OSAS患者(单纯OSAS)和23例合并OSAS和IHD的患者开始接受CPAP治疗。在治疗前后测量血浆同型半胱氨酸浓度、血清瘦素、C反应蛋白(CRP)、纤维蛋白原、血脂以及内脏脂肪标志物(MVA)。
两组患者的同型半胱氨酸、瘦素、纤维蛋白原和CRP浓度均无显著变化。在合并OSAS和IHD的患者中,血脂和MVA无变化。在单纯OSAS组中,总胆固醇和低密度脂蛋白胆固醇浓度显著降低(分别为202.5±38.5mg/dl对186.7±33.5mg/dl,p=0.001;127.3±32.9mg/dl对116.4±26.9mg/dl,p=0.02)。甘油三酯无显著变化(p=0.09)。体重指数(BMI)(30.4±3.8对30.6±3.6,p=0.5)、腰围(108.5±8.0cm对107.0±7.5cm,p=0.09)和腰臀比(1.03±0.04对1.01±0.03,p=0.07)均无显著变化。
3个月的CPAP治疗在两组患者中均未改变同型半胱氨酸和瘦素浓度。然而,它显著降低了单纯OSAS患者的血脂浓度,但在合并OSAS和IHD的患者中未降低,提示CPAP治疗对心血管危险因素有有益作用。